Regulation of expression of Na+,K+-ATPase in androgen-dependent and androgen-independent prostate cancer

British Journal of Cancer

Volumn 81, Issue 1, 1999, Pages 28-36

  Blok, L J ^a   Chang, G T G ^a   Steenbeek Slotboom, M ^a   Van Weerden, W M ^a   Swarts, H G P ^b   De Pont, J J H H M ^b   Van Steenbrugge, G J ^a   Brinkmann, A O ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Androgen dependent; Androgen independent; Androgens; Cisplatin; Na+,K+ ATPase; Prostate

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ANDROGEN; ANTIINFECTIVE AGENT; CISPLATIN; OUABAIN; POLYCLONAL ANTIBODY; POTASSIUM; SODIUM; TRITIUM;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; ELECTROCHEMISTRY; ENZYME SUBUNIT; GENE EXPRESSION REGULATION; HOMEOSTASIS; HORMONAL REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NONHUMAN; POTASSIUM CELL LEVEL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SODIUM CELL LEVEL;

ANDROGENS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL DEATH; CISPLATIN; DOWN-REGULATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MACROMOLECULAR SUBSTANCES; MALE; METRIBOLONE; MICE; MICE, NUDE; NA(+)-K(+)-EXCHANGING ATPASE; NEOPLASM TRANSPLANTATION; NEOPLASMS, HORMONE-DEPENDENT; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; TESTOSTERONE CONGENERS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0032885002     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690647     Document Type: Article

References (42)

1. Akimoto S, Ohki T, Akakura K, Masai M and Shimazaki J (1994) Chemotherapy for endocrine therapy-refractory prostate cancer. Cancer Chemother Pharmacol 35: S18-22
2. --adenosine triphosphatase in the accumulation cisdiamminedichloroplatinum(II) in human ovarian carcinoma cells, Cancer Res 51: 3677-3681
3. Bando T, Fujimura M, Kasahara K, Shihata K. Heki U, Iwasa K, Ueda A, Tomikawa S and Matsuda T (1997) Exposure to sorbitol induces resistance to cisplatin in human non-small-cell lung cancer cell lines, Anticancer Res 17: 3345-3348
4. 4-ATPase on intracellular accumulation of cis-diamminedichlorideplatinum(II) in human non-small-cell but not in small-cell lung cancer cell lines. Anticancer Res 18: 1085-1089)
5. Bando T, Fujimura M, Kasahara K and Matsuda T (1998b) Role of thromboxane receptor on the intracellular accumulation of cisdiamminedichlorideplatinum(II) in non-small-cell but not in small-cell lung cancer cell lines. Anticancer Res 18: 1079-1084
6. Blok LJ, Kumar MV and Tindall DJ (1995) Isolation of cDNAs that are differentially expressed between androgen-dependent and androgen-independent prostate carcinoma cells using differential display PCR. Prostate 26: 213-224
7. Blok LJ, De Ruiter PE and Brinkmann AO (1998) Forskolin-induced dephosphorylation of the androgen receptor impairs ligand binding. Biochemistry 37: 3850-3857
8. Chang GTG, Blok LJ, Steenbeek M, Veldscholte J, van Weerden WM, van Steenbrugge GJ and Brinkmann AO (1997) Differentially expressed genes in androgen-dependent and androgen independent prostate carcinomas. Cancer Res 57: 4075-4081
9. Chau D, von Schlippe M and Harland SJ (1997) A phase II study of continuous infusion 5-fluorouracil (5-FU) with epirubicin and cisplatin in metastatic, hormone-resistant prostate cancer: an active new regime. Eur J Cancer 33: 1230-1233
10. Charlemagne D (1993) Molecular and cellular levels of action of digitalis. Herz 18: 79-85
11. Claessens F, Alen P, Devos A, Peelers B, Verhoeven G and Rombauts W (1996) The androgen-specific probasin response element 2 interacts differentially with androgen and glucocorticoid receptors. J Biol Chem 271: 19013-19016
12. Cooney KA, McCarthy JD, Lange E, Huang L, Miesfeldt S, Montie JE, Oesterling JE, Sandler HM and Lange K (1997) Prostate cancer susceptibility locus on chromosome Iq: a confirmatory study. J Natl Cancer Inst 89: 955-959
13. Coughliu CT, Richmond RC and Page RL (1994) Platinum drug delivery and radiation for locally advanced prostate cancer. Int J Radiation Oncol Biol Phys 28: 1029-1038
14. Darzynkiewicz Z, Li X and Gong J (1994) Assays of cell viability: discrimination of cells dying by apoptosis. Methods Cell Biol 41: 15-39
15. Derfoul A, Robertson NM, Lingrel JB, Hall DJ and Litwack G (1998) Regulation of the human Na/K ATPase β1 gene promoter by mineralocorticoid and glucocorticoid receptors. J Biol Chem 273: 20702-20711
16. 4-ATPase: mechanisms underlying rapid and sustained changes in pump activity. Am J Physiol 38: C295-311
17. +-ATPase. J Membr Biol 115: 109-121
18. +-ATPase: α1-, α2-, and β1-mRNA and -protein levels at steady state. Am J Physiol 262: C484-492
19. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA and Murphy GP (1983) LNCaP model of human prostatic carcinoma. Cancer Res 43: 1809-1818
20. Kasahara K, Fujimura M, Bando T, Shibata K and Matsuda T (1996) Modulation of sensitivity to cis-diamminedichloroplatinum (II) by tromboxane A, receptor antagonists in non-small-cell lung cancer cell lines. Br J Cancer 74: 1553-1558
21. Lieberthal W, Triaca V and Levine J (1996) Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis. Am J Physiol 270: F700-708
22. 1-ATPase. J Biol Chem 269: 19659-19662
23. +-ATPase, Comp Biochem Physiol 105C: 1-9
24. McDonough AA, Geering K and Farley RA (1990) The sodium pump needs its β subunit. FASEB J 4: 1598-1605
25. Mercer RW (1993) Structure of the Na,K-ATPase. Int Rev Cytol 137C: 139-168
26. Middleton JP (1996) Direct regulation of the Na,K pump by signal transduction mechanisms, Miner Electrolyte Metab 22: 293-302
27. Munha P, Tindall DJ and Young CY (1993) Androgen induction of a human prostate-specific kalliklein, hKLK2: characterization of an androgen response element in the 5′ promoter region of the gene. Biochemistry 32: 6459-6464
28. Nelson WG and Simons W (1996) New approaches to adjuvant therapy for patients with adverse histopathologic findings following radical prostatectomy. Urol Clin North Am 23: 685-696
29. Ohmori T, Nishio K, Ohta S, Kubota N, Adachi M, Komiya K and Saijo N (1994) Ouabain-resistant non-small-cell lung-cancer cell line shows collateral sensitivity to cis-diamminedichloroplatinum(II) (CDDP). Int J Cancer 57: 111-116
30. Oliver RTD and Gallagher CJG (1995) Intermittent endocrine therapy and its potential for chemoprevention of prostate cancer. Cancer Surv 23: 191-207
31. +)-ATPase. J Bioenerg Biomembr 16: 223-232
32. Rose AM and Valdes R (1994) Understanding the sodium pump and its relevance to disease. Clin Chem 40: 1674-1685
33. Ruiz A, Bhat SP and Bok D (1995) Characterization and quantitation of full length and Iruncated Na,K-ATPase α1 and β1 RNA transcripts expressed in human retinal pigment epithelium. Genes 155: 179-184
34. Rundlett SE and Miesfeld RI. (1995) Quantitative differences in androgen and glucocorticoid receptor DNA binding properties contribute to receptor-selective transcriptional regulation. Mol Cell Endocrinol 109: 1-10
35. Sakai H, Minami Y, Kanetake H and Saito Y (1994) Chemo-endocrine therapy for prostate cancer with bone metastasis. Cancer Chemother Pharmacol 35: S23-26
36. Scheller A, Hughes E, Golden KL and Robins DM (1998) Multiple receptor domains interact to permit, or restrict, androgen-specific gene activation. J Biol Chem 273: 24216-24222
37. Schnidt JD, Gibbons RP, Murphy GP and Bartolucci A (1993) Adjuvant therapy for localized prostate cancer. Cancer 71: 1005-1013
38. +-ATPase activity and cisplatin sensitivity between transformants induced by H-ras and those induced by K-ras. Int J Cancer 58: 672-677
39. van Dijck P, Winderickx J, Heyns W and Verhoeven G (1989) Binding of androgen-receptor complexes to alpha 2u-globulin genes and to the long terminal repeat of mouse mammary tumor virus. Mol Cell Endocrinol 64: 195-204
40. van Weerden WM, de Ridder CMA, Verdaasdonk CL, Romijn JC, van der Kwast TH, Schroder FH and van Sttenbrugge GJ (1996) Seven newly developed human prostate tumor xenograft models: establishment and histopathological characterization. Am J Pathol 149: 1055-1062
41. Veronesi A, Re GL, Foladore S, Merlo A, Giuliotto N, Talamini R and Montardini S (1996) Multidrug chemotherapy in the treatment of non-elderly patients with hormone-refractory prostatic carcinoma. A phase II study. North-Eastern Italian Oncology Group (GOCCNE). Eur Urol 29: 434-438
42. Wehling M, Christ M and Gerzer R (1993) Aldosterone-specific membrane receptors and related rapid, non-genomic effects. Trends Pharmacol Sci 14: 1-3